JP2024528237A - 獣医学的ウイルス性疾患の治療方法 - Google Patents

獣医学的ウイルス性疾患の治療方法 Download PDF

Info

Publication number
JP2024528237A
JP2024528237A JP2024506795A JP2024506795A JP2024528237A JP 2024528237 A JP2024528237 A JP 2024528237A JP 2024506795 A JP2024506795 A JP 2024506795A JP 2024506795 A JP2024506795 A JP 2024506795A JP 2024528237 A JP2024528237 A JP 2024528237A
Authority
JP
Japan
Prior art keywords
animal
virus
days
viral
feline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528237A5 (OSRAM
Inventor
マレー，エドワード
ワラス，ラルフ
ウルリッヒ，ヨアヒム
ナガラジ，バサヴァ・ハンガラプラ
ホイスマン，ウィレム
Original Assignee
インターベット インターナショナル ベー． フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー． フェー． filed Critical インターベット インターナショナル ベー． フェー．
Publication of JP2024528237A publication Critical patent/JP2024528237A/ja
Publication of JP2024528237A5 publication Critical patent/JP2024528237A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024506795A 2021-08-06 2022-08-05 獣医学的ウイルス性疾患の治療方法 Pending JP2024528237A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21190172.3 2021-08-06
EP21190172 2021-08-06
EP22185716 2022-07-19
EP22185716.2 2022-07-19
PCT/EP2022/072074 WO2023012329A1 (en) 2021-08-06 2022-08-05 Method of treating veterinary viral diseases

Publications (2)

Publication Number Publication Date
JP2024528237A true JP2024528237A (ja) 2024-07-26
JP2024528237A5 JP2024528237A5 (OSRAM) 2025-08-12

Family

ID=83151800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506795A Pending JP2024528237A (ja) 2021-08-06 2022-08-05 獣医学的ウイルス性疾患の治療方法

Country Status (8)

Country Link
US (1) US20240342204A1 (OSRAM)
EP (1) EP4380578A1 (OSRAM)
JP (1) JP2024528237A (OSRAM)
AU (1) AU2022323465A1 (OSRAM)
BR (1) BR112024002195A2 (OSRAM)
CA (1) CA3226836A1 (OSRAM)
MX (1) MX2024001645A (OSRAM)
WO (1) WO2023012329A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023002233A (es) 2020-08-24 2023-03-15 Gilead Sciences Inc Compuestos fosfolipidos y usos de estos.
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0411900B8 (pt) 2003-06-26 2021-05-25 Biotron Ltd compostos e composições farmacêuticas compreendendo os mesmos
WO2012152317A1 (en) 2011-05-10 2012-11-15 Okapi Sciences Nv Compounds for use in the treatment of feline retroviral infections
GB201203180D0 (en) 2012-02-24 2012-04-11 Okapi Sciences Nv Compounds for treating parvovirus infection
IL296496B2 (en) 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
IL277160B2 (en) 2018-03-07 2024-10-01 Univ Emory 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Also Published As

Publication number Publication date
WO2023012329A1 (en) 2023-02-09
EP4380578A1 (en) 2024-06-12
AU2022323465A1 (en) 2024-02-01
US20240342204A1 (en) 2024-10-17
BR112024002195A2 (pt) 2024-04-30
MX2024001645A (es) 2024-02-27
CA3226836A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
JP7802365B2 (ja) ハンタウイルス感染症の処置のためのｍｅｋ阻害剤
ES2883639T3 (es) Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas
KR102136803B1 (ko) 바이러스 감염을 치료하기 위한 티아졸리드 화합물
Gupta et al. Bats and viruses: a death-defying friendship
US20240342204A1 (en) Method of treating veterinary viral diseases
JP2010521480A (ja) インフルエンザ治療用組成物及びキット
ES2827197T3 (es) Composiciones y procedimientos para tratar enfermedades infecciosas
CN112245429A (zh) 用于治疗rsv的组合产品
TWI656872B (zh) 甲基鹽黴素於豬飼料中之抗病毒效果
ES2230802T3 (es) Tratamiento de infeccion viral en cercos.
CN117858710A (zh) 治疗兽医学病毒性疾病的方法
JP7293225B2 (ja) 組合せ製品を用いるｒｓｖの処置
US10092647B2 (en) Canine health product containing antibodies against canine parvovirus type 2
KR102573565B1 (ko) 플라보노이드 계열 화합물 및 이를 유효성분으로 함유하는 항바이러스제
US20240327339A1 (en) Compositions and methods for treating and preventing viral infections
JP7856771B2 (ja) 核酸由来ヌクレオシドアナログおよびこれらの薬学的に許容可能な塩を含む抗ウイルス用組成物
US20250332170A1 (en) Vandetanib reduces inflammatory cytokines and ameliorates covid-19
KR20230090927A (ko) 세포내 스트레스 과립 형성 기전에 기초한 코로나바이러스 감염의 예방 또는 치료제 및 이의 병용 제제
JP5865839B2 (ja) 粘膜アジュバント組成物
HK40085365A (en) Remdesivir treatment methods
KR102065848B1 (ko) 엔테로코코스 카니테스티니(Enterococcus canintestini)균주를 함유하는 항인플루엔자 바이러스 조성물
RU2292220C1 (ru) Способ профилактики инфекционного ринотрахеита и парагриппа-3 крупного рогатого скота
Rout Carrier state in domestic and wildlife species: a debatable issue of concern in the epidemiology of foot-and-mouth disease
WO2024097158A1 (en) Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
RU2320324C1 (ru) Способ профилактики инфекционного ринотрахеита крупного рогатого скота у телят при помощи противовирусного препарата йодантипирин

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250801